The Department of Health and Human Services this week purchased $26 million worth of intravenous TPOXX (tecovirimat) to treat monkeypox, which the manufacturer expects to deliver next year. Under its contract with SIGA Technologies, HHS may still purchase additional oral and IV TPOXX, an antiviral drug approved by the Food and Drug Administration to treat smallpox and available under an investigational protocol to treat monkeypox. TPOXX is available free to states and territories through the Strategic National Stockpile, which held over 1.7 million treatment courses before the monkeypox outbreak. HHS last week declared the U.S. outbreak, which exceeds 10,000 cases, a public health emergency. 

Related News Articles

Headline
AHA is continuing its annual work to help hospitals and health systems encourage their communities to stay healthy and protect themselves against the flu and…
Headline
The Centers for Disease Control and Prevention yesterday recommended clinicians adhere to all recommendations to prevent monkeypox transmission in health care…
Headline
The Department of Health and Human Services’ Health Sector Cybersecurity Coordination Center (HC3) yesterday alerted the sector to a monkeypox-themed phishing…
Headline
Only seven of 313 Colorado health care personnel exposed to monkeypox patients this May through July developed symptoms and none developed monkeypox during the…
Headline
Monkeypox cases have dropped nearly 50% since early August, the White House said today, affirming the effectiveness of a national mitigation strategy where…
Headline
The Los Angeles Department of Public Health, along with the Centers for Disease Control and Prevention, yesterday confirmed the first death due to monkeypox in…